| pubmed-article:7407793 | pubmed:abstractText | An application of decision theory to the design of phase II clinical trials in cancer is presented. A risk function which depends on the prior distribution of the response rate, the costs of treating a patient, and the gains or losses resulting from the decision taken upon completion of the study is derived and optimal restricted sampling plans for a response rate of 20% are provided. | lld:pubmed |
